TY - JOUR
T1 - Case Series
T2 - Efficacy and Safety of Hemoadsorption With HA-330 Adsorber in Septic Pediatric Patients With Cancer
AU - Sazonov, Vitaliy
AU - Abylkassov, Ramazan
AU - Tobylbayeva, Zaure
AU - Saparov, Askhat
AU - Mironova, Olga
AU - Poddighe, Dimitri
N1 - Funding Information:
The article publication charge was supported by Nazarbayev University School of Medicine.
Publisher Copyright:
© Copyright © 2021 Sazonov, Abylkassov, Tobylbayeva, Saparov, Mironova and Poddighe.
PY - 2021/6/11
Y1 - 2021/6/11
N2 - Background: Sepsis is a frequent cause of death in hospitalized patients and, in detail, in neonatal, pediatric, and adult intensive care units (ICUs). Severe sepsis has a very poor prognosis. Indeed, the mortality rate varies between 30 and 70% during the first 7–14 days. Despite a timely and appropriate therapy, the prognosis of severe sepsis is too often negative. Therefore, new therapeutic resources are under investigation in order to further improve prognosis. Case series: Here, we reported three septic children in whom we used extracorporeal blood purification therapy with hemoadsorption device HA330 (Jafron Biomedical Co., Ltd., China), aiming to scavenge and eliminate bacterial toxins and inflammatory mediators from the blood. Discussion and Conclusion: This small case series first showed that hemoperfusion with HA330 cartridge may be an effective and relatively safe adjunctive treatment to counterbalance the cytokine storm in septic children with hematological disorders. Further studies are needed to confirm and further support its safety and efficacy in a large number of pediatric patients.
AB - Background: Sepsis is a frequent cause of death in hospitalized patients and, in detail, in neonatal, pediatric, and adult intensive care units (ICUs). Severe sepsis has a very poor prognosis. Indeed, the mortality rate varies between 30 and 70% during the first 7–14 days. Despite a timely and appropriate therapy, the prognosis of severe sepsis is too often negative. Therefore, new therapeutic resources are under investigation in order to further improve prognosis. Case series: Here, we reported three septic children in whom we used extracorporeal blood purification therapy with hemoadsorption device HA330 (Jafron Biomedical Co., Ltd., China), aiming to scavenge and eliminate bacterial toxins and inflammatory mediators from the blood. Discussion and Conclusion: This small case series first showed that hemoperfusion with HA330 cartridge may be an effective and relatively safe adjunctive treatment to counterbalance the cytokine storm in septic children with hematological disorders. Further studies are needed to confirm and further support its safety and efficacy in a large number of pediatric patients.
KW - blood purification
KW - HA-330 adsorber
KW - hemoadsorption
KW - pediatric cancer
KW - sepsis
UR - http://www.scopus.com/inward/record.url?scp=85108884010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108884010&partnerID=8YFLogxK
U2 - 10.3389/fped.2021.672260
DO - 10.3389/fped.2021.672260
M3 - Article
AN - SCOPUS:85108884010
VL - 9
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
SN - 2296-2360
M1 - 672260
ER -
